XRP $3 Bets Dominate Trading Volumes as XRP/BTC's 'Wedge' Suggests Further Rally
Since July 1, higher-level July 25 call options at strikes of $3.00 and $4.00 and the Sept. 28 expiry call at the $2.80 strike have emerged as the most traded bets, according to data source Amberdata.
A call option gives the buyer the right to buy the underlying asset at a predetermined strike price at a later date. The option represents a bullish view on the market. For instance, the $3 strike call buyer is betting that XRP's spot price will top that level by July 25. On Deribit, one options contract represents one XRP.
A closer look at the flows reveals that the higher volume ranking for the $3 calls primarily stems from buy trades. In the past 24 hours, the $3 strike call has seen 2 million contracts change hands in investor buy trades (market makers on the opposite side). Conversely, investors have been mostly sellers or writers in the $2.8 call.
The $3 call is also the most popular bet in terms of the increase in open interest, or the number of active or open contracts, in the past seven days.
The increased activity in the higher strike calls follows strengthening expectations for a spot ETF debut in the U.S. According to Bloomberg's analysts Eric Balchunas and James Seyffart, the probability that the U.S. SEC will approve a spot XRP ETF now stands at 95% – almost a done deal.
On Wednesday, fintech firm Ripple, which utilizes XRP to facilitate cross-border transactions, announced that it has applied for a national banking license at the Office of the Comptroller of the Currency (OCC).
"If approved, we would have both state (via NYDFS) and federal oversight, a new (and unique!) benchmark for trust in the stablecoin market," Ripple's CEO Brad Garlinghouse said on X.
XRP's bitcoin-denominated price, represented by the Binance-listed XRP/BTC pair, may be headed higher, having broken out of a falling wedge pattern.
The falling wedge is a bullish reversal pattern, characterized by two converging trendlines that indicate a narrowing range of price movement. The converging nature of trendlines suggests that sellers are slowly losing steam. Hence, a subsequent move above the upper trendline is said to confirm renewed bull dominance.
XRP/BTC has risen above the upper trendline, confirming the bullish breakout. The pattern indicates that the correction from the April highs has ended and the broader XRP bullish trend has resumed.
While the wedge breakout indicates that the path of least resistance is on the higher side, popular averages, 50-day, 100-day and 200-day SMAs disagree.
Both the 50- and 100-day SMAs are trending south, having recently crossed bearishly below the 200-day SMA. Note, however, that moving averages are lagging indicators and take backseat to the bullish wedge breakout.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Ripple Applies for Federal Bank Trust Charter, XRP Jumps 3%
Ripple, the digital asset firm closely associated with the XRP Ledger network, has applied on Wednesday for a national banking license at the Office of the Comptroller of the Currency (OCC), a spokesperson confirmed to CoinDesk. The license would allow the company expand its crypto services and operate across state lines under federal regulation. Ripple issues the $440 million RLUSD stablecoin regulated by the New York Department of Financial Services (NYDFS), and also provides digital asset custody services. The Wall Street Journal first reported the news earlier on Wednesday. XRP XRP, the native cryptocurrency of the payments-focused XRP Ledger network, advanced 3% on the news. Ripple's application comes after USDC issuer firm Circle (CRCL) also filed for a similar license earlier this week, a sign that stablecoin companies are seeking federal oversight as U.S. legislation to regulate stablecoins and crypto market structure advances. The House of Representatives currently has the U.S. Senate's stablecoin bill before it. Crypto custodian Anchorage Digital already holds a federal charter. "If approved, we would have both state (via NYDFS) and federal oversight, a new (and unique) benchmark for trust in the stablecoin market," Ripple CEO Brad Garlinghouse said in an X post. Garlinghouse said the company also applied for a master account at the Federal Reserve earlier in the week via Standard Custody, the New York-based trust and custody firm Ripple acquired last year. Master accounts allow banks and depository institutions to directly access the Federal Reserve, rather than require them to go through intermediary banks. If obtained, a Fed account would allow Ripple to store its stablecoin reserves such as U.S. Treasuries with the central bank and "provide an additional layer of security to future proof trust in RLUSD," Garlinghouse said. For long, crypto-focused firms such as Kraken and Caitlin Long's Custodia Bank have tried without success to obtain accounts at the Fed. UPDATE (July 2, 18:40 UTC): Adds comments from Brad Garlinghouse on bank charter and Fed master account application. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
3 hours ago
- Business Insider
Crypto Currents: Institutions buy in as global crypto regulation tightens
As Bitcoin navigates market crosscurrents and the broader crypto landscape undergoes rapid evolution, legal, institutional, and technological developments are constantly reshaping the financial world. Stay up on the crypto news that matters with 'Crypto Currents,' daily from The Fly. Join us 2PM daily for your essential briefing on the fast-moving world of cryptocurrency on FlyCast radio, available to subscribers at Also, subscribe to our YouTube channel for the Crypto Currents Fly By weekly recap. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. INSTITUTIONS FORGE AHEAD: Despite a complex regulatory environment, institutional money continued to pour into the digital asset space this week. U.S. Bitcoin spot ETFs saw a surge of confidence, with over $500M in net inflows on a single day. Fidelity's FBTC and BlackRock's IBIT led the charge, pulling in $166M and $153M, respectively. Corporate adoption also hit major milestones, as design software powerhouse Figma (FIG) revealed in its IPO filing a significant holding of $70M in Bitcoin ETFs. Over in Europe, the trend was just as strong. Germany's largest financial group, Sparkassen, announced it plans to provide cryptocurrency trading to its retail customers by summer 2026, while banking giant Deutsche Bank (DB) is proceeding with its initiative to introduce a crypto custody service in the same year. A WEEK OF REGULATORY RECKONING: Regulators and lawmakers globally made their presence felt this week. In the United States, New York Attorney General Letitia James publicly urged Congress to enact more robust federal regulations to bolster investor protections. On the enforcement side, the U.S. Treasury Department sanctioned a cryptocurrency wallet identified in connection with a ransomware attack, signaling a tougher stance on illicit activities. In another move toward greater oversight, stablecoin issuer Circle is pursuing a U.S. National Trust Bank charter. Internationally, Turkey's Financial Crime Investigation Board announced strict new rules for crypto platforms, requiring detailed source and purpose checks for transactions. In contrast, the European Union's new MiCA regulations are fostering growth, attracting exchanges like Bybit and OKX to broaden their services in the region. RIPPLE'S DUAL STRATEGY: Ripple, the company behind XRP, was at the center of two major developments this week. In a move that could finally end a years-long legal saga, the company dropped its cross-appeal against the U.S. Securities and Exchange Commission. In a separate, major strategic push, Ripple announced it is applying for a national bank charter from the OCC and a Fed Master Account. This forward-looking move aims to allow Ripple to hold reserves for its stablecoin directly with the Federal Reserve, a strategy designed to set a new benchmark for trust in the stablecoin market. BRIDGING TRADITIONAL AND DECENTRALIZED FINANCE: The trend of merging traditional assets with blockchain technology gained serious momentum. In a pioneering move, U.S. company Everything Blockchain (EBZT) announced its intention to become the first publicly-traded OTC firm to fully tokenize its stock on a blockchain. In a similar development that brings a major traditional asset onto the blockchain, shares of the prominent chipmaker Nvidia (NVDA) are now tradable on the Solana (SOL) blockchain in the form of tokenized stocks. On the consumer front, Bitget Wallet partnered with Mastercard (MA) and Immersve to launch new zero-fee crypto cards, aiming to simplify the process of using crypto for daily purchases.
Yahoo
3 hours ago
- Yahoo
Why Summit Therapeutics Stock Soared 8% Higher Today
A large, well-capitalized peer is apparently interested in a partnership deal with the company. This could be worth up to $15 billion in total, according to a media report. 10 stocks we like better than Summit Therapeutics › One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (NASDAQ: SMMT) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal. That rise bettered the S&P 500's (SNPINDEX: ^GSPC) 0.8% increase by several orders of magnitude. The media outlet in question was Bloomberg, which that morning published an article asserting that AstraZeneca is in talks with Summit about a partnership between the two companies. According to unnamed "people familiar with the matter," the piece stated that such a partnership would center on the investigational lung cancer treatment ivonescimab. The drug, which Summit licenses from Chinese peer Akeso, has recently attracted much attention from the healthcare community and investors alike. This was due to its impressive performance in a late-stage clinical trial. Bloomberg's sources said that the terms of a potential deal were still being hashed out. They might include an up-front payment of several billion dollars, and several milestone payments over time (this kind of structure is common in pharmaceutical industry licensing/partnership arrangements). All told, a deal between the two companies could pay out as much as $15 billion. Both Summit and AstraZeneca declined comment on the Bloomberg article. When a drug development program attracts $15 billion worth of interest from a major industry player with deep pockets, it's almost indisputably a win. If the Bloomberg report is accurate and a deal is indeed in the works (and is ultimately agreed upon), it would open a great, powerful, and quick road to success for Summit. It's little wonder investors were so happy about the possibility. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Why Summit Therapeutics Stock Soared 8% Higher Today was originally published by The Motley Fool
